On the American stock market, we are currently witnessing an excellent trend, with new highs being set almost every day. Our robots, including the ones mentioned below, have capitalized on this momentum, earning over 4% in just the past week. These robots can be found at the following links:
These robots are particularly suitable for traders who prefer a balanced strategy. The Day Trader robots focus on stocks with medium and high volatility, allowing traders to adapt their trading algorithms based on market activity.
Here's how these robots operate:
Step 1: The algorithms evaluate the short- and medium-term trends for each stock. Step 2: Using a proprietary set of technical indicators, the robots identify signals to open trades. Step 3: Based on the volatility and direction of the trends, separate algorithms determine the position size for each trade.
Once a trade is initiated, the AI robots set a "Take Profit" order, with the distance determined by the current market volatility. To exit a position, the robots utilize a 3% stop loss of the opening price and a flexible trailing stop, which helps preserve profits in case of a market reversal.
Please note that the robot's trading results are displayed without the use of margin. For comprehensive trading statistics and an equity chart, you can click on the "Show More" button on the robot's page. The "Open Trades" tab allows you to observe how the AI robot selects and executes trades in real-time, while the "Closed Trades" tab provides a record of all past trades conducted by the robot.
Join us as we explore the exciting world of automated trading and uncover the potential of NVAX and other stocks in this exhilarating market surge.
The 10-day RSI Oscillator for NVAX moved out of overbought territory on October 06, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 instances where the indicator moved out of the overbought zone. In of the 20 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
The Momentum Indicator moved below the 0 level on October 15, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NVAX as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NVAX turned negative on October 09, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .
NVAX moved below its 50-day moving average on October 23, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NVAX broke above its upper Bollinger Band on October 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 55 cases where NVAX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVAX advanced for three days, in of 251 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 122 cases where NVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (36.101) is normal, around the industry mean (24.283). P/E Ratio (3.766) is within average values for comparable stocks, (54.634). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.158). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (1.305) is also within normal values, averaging (351.737).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company which engages in development of novel recombinant vaccines
Industry Biotechnology